Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib with Indoximod and Chemotherapy in Pediatric Brain Cancer
NCT05106296Phase 1Recruiting
- Start
- Feb 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibrutinib in brain cancer (2 arms). Primary endpoints: Regimen-Limiting Toxicity at 90 days and Objective Response Rate at 5 years. Started Feb 2022; status: recruiting.
02
Drugs
ibrutinib
03
Conditions
brain cancer
Beyond the preview
Go deeper on NCT05106296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106296.